// App-Quantinova.ai

P336 : Can Mesenchymal Stem Cell (MSC) apoptosis be used as a biomarker for treatment success in perianal fistulising Crohn’s Disease (pCD)? Findings from a prospective pilot study

Researchers

Presenter

  • Iqbal, N

Principal Investigators

  • Constable, L

  • Tozer, P

  • Lung, P

  • Hart, A

  • Powell, N

Medical Centers

  • St Mark's Hospital, Robin Phillips Fistula Research Unit, London, United Kingdom

  • Imperial College London, Department of Surgery and Cancer, London, United Kingdom

  • Kings College London, Department of Inflammation Biology- School of Immunology and Microbial Science, London, United Kingdom

  • Imperial College London, Department of Metabolism Digestion and Reproduction, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

Disease

  • Perianal fistulising Crohn’s disease

  • Anal fistula

  • Crohn's disease

Biomarkers

  • Annexin V

  • Peripheral blood mononuclear cell

  • Mesenchymal stem cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved